Q3 FY2013

Investor Update

February 13, 2013

Disclaimer

Statements made in this Investor Update describing the Company’s objectives, projections, estimates, expectations may be “Forward-looking Statements” within the meaning of all applicable laws and regulations. Actual results could differ from those expressed or implied. Important factors that could make a difference to the Company’s operations include economic conditions affecting demand, supply and price conditions in the domestic and overseas markets in which the Company operates, changes in government regulations, tax laws, other statutes and other incidental factors.

2

Q3 FY2013 Summary Quarterly Performance

Consolidated Performance Highlights: YTD FY2013 Vs. YTD FY2012

o Sales increased by 14.6% to Rs. 1,941 crore

o Medical equipment and consumables grew by 14.5% yoy

o Interventional devices and tools grew by 16.0% yoy

o EBITDA increased by 11.2% to Rs. 517 crore; margins hold steady at 27%

o PAT increased by 1.4% to Rs. 368 crore; margins decline by 2.5%

o Net Debt of Rs. 973 Crore and a Net Debt to Equity ratio of 0.45 x as at December 31, 2012

3

Q3 FY2013 Summary Quarterly Performance

Corporate & Business Highlights

o Appointed Mr. Srinatha A N as the new Company Secretary and Compliance Officer

o Received a BBB+ rating from Brickwork Ratings for the parent Company’s fund based working capital facilities. The rating indicates a stable outlook

o Tie up with a medtech company to enhance penetration in Asian markets for the Dior® and Freeway® , drug-eluting balloons product line

o Launched Powerheart® G5 AED in Italy and Norway and Burdick® 4250 Vision Holter in US

Strategic Initiatives

OEHL Malaysia production facility

o Value Addition is currently being performed.

o 80% equipment received and is being installed. Remaining 20% to be installed in the coming quarter. Initiated CE audit and ISO certification process.

4

Q3 FY2013 Summary Quarterly Performance

New Client Wins

Medical Equipment and Consumables (Non Invasive Segment)

5

o US: Chicago Metra, Entergy, Wisconsin Department of Corrections for AEDs

o Canada: Heart and Stroke Foundation of British Columbia for AEDs

o UK: Red Cross tender for AEDs

o Italy: Chosen official AED supplier of Football National Teams (10 teams) for the next 4 years

o Germany: AEDs for Ministry of Interiors, Government tender deal and for J&J German headquarters

o Philippines: Philippine Airlines AED order through our alliance with Airbus/Innovint

o India : GVK EMRI for AEDs

o France: Tender for the 506 Series monitors from France’s first public GPO UNIHA

Interventional Devices and Tools (Invasive Segment)

o Tenders / large order wins in Poland, Venezuela, Korea and India

Q3 FY2013 Industry Trends & Policy Changes Quarterly Performance

6

Recent Developments

o US implements 2.5% medical device tax on all medical devices sold in the country.

o The European Society of Cardiology (ESC), the American College of Cardiology (ACC) and the American Heart Association (AHA) convened, together with the World Heart Federation (WHF) and released a new universal definition for myocardial infarction (MI) or Heart Attacks. This new definition clarifies the controversial area of procedural related MI and will be the gold standard for diagnosis and clinical trial endpoints. A new ECG STEMI criterion was released and going forward all ECG systems must comply with the newly set criterion.

o Leading medical groups have requested the Department of Health and Human Services, USA to delay the implementation of Stage 3 of meaningful use of electronic health records (EHRs) as providers are still trying to implement stages 1 and 2.

o AED manufacturers, advocates and related industry in the US continue to urge the FDA to reconsider its proposed reclassification of automated external defibrillators; from Class III 510 (K) to Class III PMA devices.

Q3 FY2013 Financial Highlights Quarterly Performance

Consolidated Financials

7

Q3 and YTD FY13 operating margins absorbed the total impact of the R&D spends, raw material prices remain stable, however general pricing pressure witnessed.

y-o-y Q2 q-o-q y-o-y

(Rs. Cr) FY2013 FY2012 Growth (%) FY2013 Growth (%) FY2013 FY2012 Growth (%)

Sales 619 611 1.2% 607 1.9% 1,941 1,694 14.6%

Gross Profit 261 295 (11.6%) 267 (2.4%) 846 805 5.1%

% of Sales 42.1% 48.2% 44.0% 43.6% 47.5%

EBITDA 163 167 (2.7%) 162 0.7% 517 465 11.2%

% of Sales 26.3% 27.4% 26.6% 26.6% 27.4%

PAT 113 125 (9.5%) 116 (2.6%) 368 363 1.4%

% of Sales 18.3% 20.5% 19.2% 18.9% 21.4%

Basic EPS (Rs.) 4.67 5.16 (9.5%) 4.80 (2.6% 15.17 14.96 1.4%

Q3 Nine Months

Q3 FY2013 Financial Highlights Quarterly Performance

Leverage Profile

o The long term debt resides in the books of the Company’s subsidiaries domiciled in the US and is matched in currency by the subsidiaries’ inflows and assets. Such long term debt has varied repayment schedules (bi-annual & quarterly) and varied tenures (between 3 to 4 years)

o Our debt servicing schedules and utilizations of lines of credit are in consonance with our Lenders and we abide by the terms and timelines contracted with our Lenders]

(Rs. Cr) 31st Dec

2012 30th Mar

2012

Gross Debt 1,065 1,172

Cash & Bank Balances 91 174

Net Debt 973 998

Equity 2,138 1,699

Gross Debt / Equity (x) 0.48X 0.69x

Net Debt / Equity (x) 0.45X 0.59x

Notes: 1. The long term debt repayment schedule presented above is on the Debt balance as at March 31st, 2012

8

Q3 FY2013 Financial Highlights Quarterly Performance

Operating Working Capital Cycle

9

178199

209

131

160 165

79 78 78

32 39 34

Mar-12 Sep-12 Dec-12

Operating Cycle Trade Receivables

Inventory Trade Payables

Q3 FY2013 Financial Highlights Quarterly Performance

Other Key Financial Metrics

The tax expense reflects the total of all tax provided and paid during this period across our various entities as per the laws prevailing in their respective countries of domicile

(Rs. Cr) Q3

FY2013 Q3

FY2012 YTD

FY2013

R&D 22.37 23.78 65.41

% of Sales 3.6% 3.9% 3.4%

Capex 28.94 - 91.94

% of Sales 3.9% 4.7%

10

(Rs. Cr) YTD FY2013

Consolidated Tax 22.9

Effective Tax Rate (ETR) 5.8%

o Gross additions to capex for Q3FY13 was Rs. 28.94 Crore, which was hitherto, lying as Advances paid to Suppliers of Capital Goods in Other Non Current Assets as at March 31, 2012

o Capex deployed towards machinery and equipment in India and Malaysia

Q3 FY2013 Segment Highlights Quarterly Performance

Consolidated Sales by Segment

Sales Share by Segment

11

Sales Share by Currency (YTD FY13)

YTD FY2013 growth excluding currency impact:

o Consolidated Net Sales: 7%

o Medical Equipment (Non Invasive) segment: ~7%%

o Interventional Devices (Invasive) segment: ~ 10%

y-o-y Q2 q-o-q

FY2013 FY2012 Growth (%) FY2013 Growth (%)

Avg. Forex Rates

USD / INR 52.97 48.95 8.2% 51.93 2.0%

Euro / INR 70.30 66.07 6.4% 68.24 3.0%

Closing Forex Rates

USD / INR 54.78 53.26 2.9% 52.70 3.9%

Euro / INR 72.26 68.90 4.9% 68.15 6.0%

Q3

78% 77% 81% 80% 79%

21% 22% 18% 19% 20%1% 1% 1% 1% 1%

Q3 FY12 Q4 FY12 Q1 FY13 Q2 FY13 Q3 FY13

Medical Equipment Interventional Devices Non Medical

Q3 FY2013 Segment Highlights Quarterly Performance

Medical Equipment and Consumables (Non Invasive Segment)

o Launched Powerheart® G5 AED in Italy and Norway and Burdick® 4250 Vision Holter in US

o AMDL Healthcare launched Mediaid’s Model AD Premium 910 Anaesthesia Workstation, Vent Care 410 ICU Ventilator and Model Vent Mini Portable Ventilator in India

o Signed distribution agreements with McKesson, providing access to their corporate and field programs

o Renewed Henry Schein Passport Program (preferred vendor program for key cardiology projects)

o Successfully renewed the IDN agreement with McLaren Health Care Corporation covering stress, ECG, RMS, Pyramis and supplies. CSC is the exclusive provider of these products in their 9 hospitals

o AMDL Healthcare revamped sales team in Ahmedabad, Surat, Pune and Nagpur & reinforced partner distribution presence in Bihar and Orissa

Sales Share by Product Utility

Notes: 1. Monitoring and measurement products include cardiac, vital signs and anaesthesia monitoring technologies 2. The Treatment business refers to the hospital and public access revenues from the sale of all defibrillator products 3. Vascular Diagnostics include revenues generated from sale of PAD diagnostic equipment and its accessories

12

y-o-y Q2 q-o-q y-o-y

(Rs. Cr) FY2013 FY2012 Growth (%) FY2013 Growth (%) FY2013 FY2012 Growth (%)

Monitoring & Measurement 352 266 32.3% 320 10.0% 1,029 748 37.6%

Treatment 129 198 (34.8%) 159 (18.9%) 504 587 (14.1%)

Vascular Diagnostics 11 13 (15.4%) 7 57.1% 28 28 0.0%

Total Sales 492 477 3.1% 320 53.8% 1,561 1,363 14.5%

Q3 Nine Months

56% 61% 56% 56%72%

42% 37% 43% 43%26%

2% 2% 2% 2% 2%

Q3 FY12 Q4 FY12 Q1 FY13 Q2 FY13 Q3 FY13

Monitoring & Measurement Treatment Vascular Diagnostics

Vascular 98%

Orthopedics 1%

Urology1%

Q3 FY2013 Segment Highlights Quarterly Performance

Interventional Devices and Tools (Invasive Segment)

Sales Share by Product Applicability (Q3 FY13)

Notes: 1. Urology includes Gastroenterology and Gynaecology

13

o E-Magic Plus which was launched in India in Q2 FY2013 received overwhelming response from Indian Cardiologists

o New distributor appointed for Minas Gerais state in Brazil

o Enhanced Indian distribution; added 11 new distributors across 10 Tier I and II cities

o Tie up with a medtech company to enhance penetration in Asian markets for Dior ® and Freeway®, drug eluting balloons product line

o Devon Innovations launched two new products in the disposable medical devices segments – central venous catheter sets and cystoscopes

y-o-y Q2 q-o-q y-o-y

(Rs. Cr) FY2013 FY2012 Growth (%) FY2013 Growth (%) FY2013 FY2012 Growth (%)

Vascular 124 126 (1.6%) 114 8.8% 362 310 16.8%

Orthopedics 1 1 0.0% 1 0.0% 3 3 0.0%

Urology 1 3 (66.7%) 2 (50.0%) 4 5 (20.0%)

Total Sales 126 130 (3.1%) 159 (20.8%) 369 318 16.0%

Q3 Nine Months

Q3 FY2013 Segment Highlights Quarterly Performance

14

Sales Share by Entities

OCI OCCL OEHL AMDL Others

Consolidated Sales by Subsidiaries

y-o-y Q2 q-o-q

(Rs. Cr) FY2013 FY2012 Growth (%) FY2013 Growth (%)

OCI 188 171 9.9% 201 (6.5%)

OCCL 257 274 (6.2%) 255 0.8%

OEHL 124 126 (1.6%) 114 8.8%

AMDL 10 10 0.0% 13 (23.1%)

Others 40 30 33.3% 24 66.7%

Total 619 611 1.3% 607 2.0%

Q3

28%

45%

20%

2% 5%

Q3 FY2012

30%

42%

20%

2% 6%

Q3 FY2013

Opto Circuits: At a Glance Company Overview

A fast growing multinational medical device company

15

Ma

rke

t

Le

ad

ers

hip

Revenue and PAT CAGR of more than 50% over the last 5 years with strong margins

Conservative balance sheet with low leverage; Net Debt to Equity of 0.45X as of Dec 31, 2012

FY2012 ROCE of 20% and ROE of 34%

Str

on

g F

ina

nci

al

P

erf

orm

an

ce

Best

-in

-Cla

ss

Op

era

tio

ns

World class manufacturing facilities across North America, Europe and Asia

Investments in R&D to maintain a healthy pipeline of innovations and product developments

6 global R&D centres with highly skilled and integrated teams

205 global patents across product lines as at December 31, 2012

Global sales offices and relationship with marquee distributors

Leader in cardiac and vital signs monitoring, emergency cardiac care, vascular treatments and sensing technologies

USFDA listed and CE marked products which are sold in over 150 countries

Partnerships with leading OEMs and medical institutions across the value chain

Well-known brands include Cardiac Science, Criticare Systems, Eurocor and Mediaid

Distribution Network and Target Customers Company Overview

Global distribution network catering to a diversified range of end customers

16

Global Distribution Network Target Customers

Primary Care & Physician Offices

Hospitals & Rehab Centers

Dental Offices

Military & Veteran Clinic

Community Centers

Surgery Centers

o OEM: Customized full service solutions

o White labelled: Consumables and accessories for group purchase organizations/distributors

o Branded Consumables

Global Offices

India USA Germany

Malaysia Singapore UK

France Denmark Japan

Poland UAE China

North America

Europe

South America

Australia

Asia

North Africa

Revised organization structure to focus on the two main business segments

17

Opto Circuits (India) Ltd. (OCIL)

Unetixs Vascular Inc.

Criticare Systems Inc.

Opto Cardiac Care Ltd. (OCCL)

Opto Eurocor Healthcare Ltd.

(OEHL)

Advanced Micronic Devices Ltd.

(AMDL)

Cardiac Science Corp.

Eurocor GmbH

Eurocor Singapore Pte Ltd.

Eurocor Asia Sdn Bhd.

N.S. Remedies Pvt. Ltd.

Opto Circuits (Malaysia) Sdn Bhd.

Opto Infrastructure Ltd.

Ormed Medical Technologies Ltd.

Non Invasive Segment

Invasive Segment

Non Medical Segment

Organization Structure Company Overview

96.85% 59.71%

Devon Innovations Pvt. Ltd.

Maxcor Lifescience Inc.

Others

87.2%

Note: 100% stake held by the Parent Company unless specifically mentioned

Mediaid, Inc.

Monitoring Treatment Diagnostics

Cardiac Monitoring

Defibrillation Products Vascular Diagnostic Systems Vital Signs Monitoring

Anesthesia Monitoring

Thermometers

Consumables, Accessories and Services

Global market opportunity: ~ $14 billion dollars

Automated and semi-automated External Defibrillators

Portable Multi-Parameter Monitor

Cardiac Monitoring Q-Stress System

Product Portfolio Company Overview

Medical Equipment and Consumables (Non Invasive Segment)

18

Vascular Orthopedics Urology,

Gastroenterology and Gynaecology

Cardiac Stents Hip Implants Catheters

Drug Coated Balloons Suction Devices Stents

Angioplasty Peripherals Surgical Tools

Physiotherapy Products Guidewires

Dilator Sets, Needles, Baskets, Injectors

Global market opportunity: ~ $8 billion dollars

Hip Implants Urology - Catheter Set Cardiac Stent and Drug coated Balloon

Product Portfolio Company Overview

Interventional Devices and Tools(Invasive Segment)

19

Definitions & Glossary

20

o AED: Automated External Defibrillator

o CE: Conformité Européenne

o DEB: Drug Eluting Balloons

o OEM: Original Equipment Manufacturer

o Holter: A portable device for continuously monitoring the electrical activity of the heart for 24 hours or more.

o ISO: International Organization for Standardization

o Ventilator: A machine designed to mechanically move breathable air into and out of the lungs, to help a patient who is physically unable to breathe or is breathing insufficiently

o GPO: Group purchase organization

o EMRI: Emergency Management and Research Institute that handles medical, police and fire emergencies through the “1-0-8- Emergency Service’

o USFDA: US Food and Drug Administration

o OEM: Original Equipment Manufacturer

o ECG: Electronic Cardiogram

o IDN: Integrated Delivery Network

o RMS: Cardiac Rehabilitation Management System

o Net Current Assets / Net Working Capital (NWC): (All Current Assets) minus (All Current Liabilities excluding short term borrowings and current maturities of long term debt)

o Net Debt: (Long term borrowings excluding Other loans and advances) plus (Short term borrowings excluding Other loans and advances) plus (Current maturities of long term debt) minus (Cash & Bank Balances)

o Working Capital Cycle: (Component / Sales)* 365

o Operating Cycle: (Days Inventory Outstanding) plus (Days Receivables Outstanding) minus (Days Payable Outstanding)

Industry Financials

# 83, Electronics City, Bengaluru - 560 100, INDIA

Phone : +91 80 2852 1040/ 41/ 42 Fax: +91 80 2852 1094 Web: www.optoindia.com

Subsidiary Websites: www.cardiacscience.com | www.csiusa.com | unetixs.com | www.amdlcorp.com|www.mediaidinc.com | www.optoeurocor.com|

www.eurocor.de|www.nsremedies.com|www.devoncath.com|www.ormedortho.com

Shalaka Parab, Opto Circuits shalaka@optoindia.com

Namita Dandekar, Opto Circuits namita@optoindia.com

Saket Somani, Churchgate Partners saket@churchgatepartnersindia.com